<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25546663</article-id>
      <article-id pub-id-type="pmc">4602607</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000000248</article-id>
      <article-id pub-id-type="art-access-id">00248</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>3600</subject>
        </subj-group>
        <subj-group>
          <subject>Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intestinal Pseudo-Obstruction in Systemic Lupus Erythematosus: A Case Report and Review of the Literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jian-lin</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Gang</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Tong</given-names>
          </name>
          <degrees>PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wei</surname>
            <given-names>Jiang-peng</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Zhang.</surname>
            <given-names>Ming</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>From the Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China</aff>
      <author-notes>
        <corresp>Correspondence: Gang Liu, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China (e-mail: <email>landmark1503@sina.com</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>02</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <volume>93</volume>
      <issue>29</issue>
      <elocation-id>e248</elocation-id>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0">http://creativecommons.org/licenses/by-nc-sa/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-93-e248.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Intestinal pseudo-obstruction (IPO) is a rare but dangerous complication of systemic lupus erythematosus (SLE) when the patient has no other manifestations except gastrointestinal symptoms. We performed 1 patient with a 2-month history of recurrent vomiting and abdominal distension. She admitted past surgical histories of cesarean section and appendectomy. A physical examination revealed tenderness in the right lower abdominal on palpation and bowel sounds were weak, 2 to 3&#x200A;bpm. An x-ray and CT of her abdomen showed intestinal obstruction. The initial diagnosis was adhesive intestinal obstruction. She received surgical treatment because her symptoms had gradually become more frequent and persistent. But she vomited again 2 weeks later after the surgery. Further immunology tests indicated that she had an IPO secondary to SLE. We treated the patient with methylprednisolone pulse for 3 days and followed by prednisone orally. The patient had a good response. Complete remission was achieved on 8 years follow-up.</p>
        <p>The importance of IPO secondary to SLE lies in an early diagnosis. After the diagnosis is established, immunosuppressive therapy should be the initial and first-line treatment, and surgical intervention is often disappointing and should be carefully avoided. It is necessary to enhance awareness of doctors to IPO secondary to SLE.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by production of autoantibodies directed against nuclear and cytoplasmic antigens, affecting several organs. The prevalence rate of SLE was estimated to be 30 to 70 cases per 100,000 persons in china.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Clinical presentations are various depending on involved organs. The primary gastrointestinal symptoms were only 3.6% of patients with SLE.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Gastrointestinal symptoms mostly include abdominal pain, vomiting, diarrhea and/or constipation, abdominal distension, and weight loss. Intestinal pseudo-obstruction (IPO) is a rare but dangerous complication of SLE. We report a rare case of a patient with IPO secondary to SLE who was misdiagnosed and had a surgery because of the sole gastrointestinal symptoms. We compare our new case with the results of a literature review (39 previously reported cases) and discuss the main characteristics, diagnosis, treatment, and outcome of IPO secondary to SLE.</p>
    </sec>
    <sec sec-type="methods">
      <title>PATIENTS AND METHODS</title>
      <sec sec-type="subjects">
        <title>Patient and Literature Review</title>
        <p>We performed a PubMed (National Library of Medicine, Bethesda, MD) search using the terms &#x201C;(Systemic lupus erythematosus) AND Intestinal pseudo-obstruction,&#x201D; retrieving all articles published in English up to August 2014. We combined these data with the new case reported here to describe in depth the IPO secondary to SLE.</p>
      </sec>
      <sec sec-type="methods">
        <title>Statistical Methods</title>
        <p>Quantitative data were expressed as median and range, and qualitative data as numbers and percentages. The chi-square test was used to compare misdiagnosis and efficacy between groups, differences with <italic>P</italic>-values less than 0.05 were considered significant.</p>
      </sec>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>In January 2006, a 42-year-old woman presented with a 2-month history of recurrent vomiting, several times a day, the vomit was food and gastric juice, accompanied by abdominal distension and 7&#x200A;kg weight loss. She admitted past surgical histories of cesarean section and appendectomy. Vital signs and physical examination were normal, with the exception of tenderness in the right lower abdominal on palpation and bowel sounds were weak, 2 to 3&#x200A;bpm. Initial bloods tests revealed hypoproteinemia (ALB: 27&#x200A;g/L) and hypokalemia (K<sup>+</sup>: 2.4&#x200A;mmol/L). An x-ray and CT of her abdomen showed intestinal obstruction. Gastroscopy and colonoscopy were normal.</p>
      <p>The patient was commenced on standard internal medical treatment for 2 weeks, but her symptoms had gradually become more frequent and persistent. She received surgical treatment. Slightly adhesive intestinal obstruction was observed during the operation, but it seemed that her slightly adhesive intestinal obstruction couldn&#x2019;t lead to so serious symptoms.</p>
      <p>The patient remained symptom-free for 2 weeks until she vomited again. Her endocrine laboratory tests were normal. Immunology laboratory tests revealed the following abnormalities: CRP: 0.92&#x200A;mg/dL (0&#x2013;0.8&#x200A;mg/dL), IgM: 17&#x200A;mg/dL (63&#x2013;277&#x200A;mg/dL), C3: 28.2&#x200A;mg/dL (83&#x2013;193&#x200A;mg/dL), C4: 10&#x200A;mg/dL (12&#x2013;36&#x200A;mg/dL), anti-histone antibody and anti-dsDNA antibody were positive, antinuclear antibody was positive, titer of 1:400, nuclear membrane type. Immunology tests supported a diagnosis of SLE.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> An x-ray and CT of her abdomen showed IPO. We treated the patient with 1&#x200A;g of methylprednisolone pulse for 3 days and followed by prednisone 1.5&#x200A;mg/kg/day orally. Three days later, her abdominal symptoms rapidly reverse, and 4 weeks later, her symptoms were complete resolved. The corticosteroid was tapered and low dosage of the drug was administered continuously. Eight years passed, the patient has remained symptom-free.</p>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <sec>
        <title>Comparison With Literature</title>
        <p>IPO secondary to SLE is rare: we identified 39 cases in the literature. Including the new case, IPO secondary to SLE has been reported in 37 female,<sup><xref rid="R4" ref-type="bibr">4</xref>&#x2013;<xref rid="R24" ref-type="bibr">24</xref></sup> and 3 male,<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> yielding a female to male sex ratio of 12.3. Mean age of the patients at diagnosis was 32.5 (10&#x2013;57) years. Epidemiologic characteristics of these 40 cases are summarized in Table <xref ref-type="table" rid="T1">1</xref>.</p>
        <table-wrap id="T1" position="float">
          <label>TABLE 1</label>
          <caption>
            <p>Epidemiologic Characteristics in 40 Patients</p>
          </caption>
          <graphic xlink:href="medi-93-e248-g001"/>
        </table-wrap>
      </sec>
      <sec>
        <title>Clinical Features and Diagnosis</title>
        <p>Gastrointestinal symptoms of IPO secondary to SLE conclude abdominal pain (80%), vomiting (78%), diarrhea and/or constipation (70%), abdominal distension (63%), and weight loss (33%).</p>
        <p>Hypoactive/absent bowel sounds (53%) and abdominal tenderness (28%) were the most commonly described in abdominal physical examination. However, some cases did not describe the physical examination, and thus hypoactive/absent bowel sounds and abdominal tenderness may be underestimated 39 patients had other symptoms of other systems except digestive system, only 1 case (our new case) had the sole symptoms of digestive system. In all the 40 cases, 16 (40%) patients were misdiagnosed.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R8" ref-type="bibr">8</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Gastrointestinal symptoms were the initial manifestation of SLE in 16 patients,<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R8" ref-type="bibr">8</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> 11 cases (69%) of them were misdiagnosed.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> While only 5 cases (21%) were misdiagnosed in other 24 patients.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> The patients whose initial manifestation was gastrointestinal symptoms were more likely to be misdiagnosed (<italic>P</italic>&#x200A;&lt;&#x200A;0.001). Clinical features observed in the 40 cases are summarized in Table <xref ref-type="table" rid="T2">2</xref>.</p>
        <table-wrap id="T2" position="float">
          <label>TABLE 2</label>
          <caption>
            <p>Clinical Features in 40 Patients</p>
          </caption>
          <graphic xlink:href="medi-93-e248-g002"/>
        </table-wrap>
      </sec>
      <sec>
        <title>Treatment and Outcomes</title>
        <sec>
          <title>Surgical Treatment and Outcomes</title>
          <p>Eleven patients (28%) received surgical treatment as the initial treatment,<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> all of them were relapsed after surgery, and 6 of them relapsed in several weeks, 2 patients relapsed in 1 year after surgery, the others did not describe the exact time. When the diagnosis of IPO secondary to SLE was established, all the patients received corticosteroids treatment and had a good response to the corticosteroids treatment.</p>
          <p>Notably, 10 patients (63%) had a surgery in patients whose initial manifestation were gastrointestinal symptoms,<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R24" ref-type="bibr">24</xref>&#x2013;<xref rid="R26" ref-type="bibr">26</xref></sup> 6 patients had an unnecessary surgery,<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> and 3 patients had once more unnecessary surgery because of misdiagnosis.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Only 1 patient received surgery because of small bowel perforation.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> After the diagnosis was established, all of the 10 patients received corticosteroids treatment and had a good response.</p>
        </sec>
        <sec>
          <title>Drug Treatment and Outcomes</title>
          <p>Corticosteroids (methylprednisolone and prednisone) were used as the initial and first-line immunosuppressive therapy in 27 patients (68%),<sup><xref rid="R4" ref-type="bibr">4</xref>&#x2013;<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>&#x2013;<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>&#x2013;<xref rid="R25" ref-type="bibr">25</xref></sup> 18 of them were given pulses of high dose corticosteroids (500&#x200A;mg or 1000&#x200A;mg/day),<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R11" ref-type="bibr">11</xref>&#x2013;<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R18" ref-type="bibr">18</xref>&#x2013;<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> and 9 patients were discharged on 1 to 2&#x200A;mg/kg/day methylprednisolone or prednisolone.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> Twenty-two (81%) of them had a good response to corticosteroids. Five patients (19%) were ineffective.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> After failure of corticosteroids treatment, 2 patients received surgical treatment and followed by immunosuppressive therapy,<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> 1 patient received intravenous cyclophosphamide (750&#x200A;mg),<sup><xref rid="R23" ref-type="bibr">23</xref></sup> 1 patient received tacrolimus,<sup><xref rid="R14" ref-type="bibr">14</xref></sup> 1 patient losed follow-up.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> All the 4 patients who received treatment had a good response.</p>
          <p>Cyclophosphamide was used in 8 cases (20%),<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> 6 of them were used in combination with corticosteroids.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Two patients who received only cyclophosphamide had a good response.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p>
          <p>Other drugs, such as Prokinetic drugs (10%),<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Hydroxychloroquine (5%),<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> and Octreotide (5%),<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> were always used in combination with corticosteroids. It is difficult to conclude whether these drugs were effective because the patients also received immunosuppressive therapy. Treatments administered in the 40 cases are summarized in Table <xref ref-type="table" rid="T3">3</xref>.</p>
          <table-wrap id="T3" position="float">
            <label>TABLE 3</label>
            <caption>
              <p>Initial Treatment in 40 Patients</p>
            </caption>
            <graphic xlink:href="medi-93-e248-g003"/>
          </table-wrap>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>IPO and protein losing enteropathy are the most common identifiable gastrointestinal complications of SLE, though other reasons such as superior mesenteric venous thrombosis, pancreatitis, peritonitis, and liver impairment could also occur in SLE.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Including the new case, 40 cases of IPO secondary to SLE have been reported so far, 39 patients had other symptoms of other systems except digestive system. In the new case we reported here, IPO was her initial and sole manifestation.</p>
      <p>IPO is defined as small bowel obstruction that occurs in the absence of mechanical or obstructive factors. The pathogenesis in SLE-related IPO remains unclear but the most probable underlying pathophysiology is of intestinal vasculitis of the visceral smooth muscles leading to damage and hypomotility.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Causes of IPO can be categorized into primary and secondary causes. Smooth muscle disorders, including familial visceral myopathy and sporadic visceral myopathy, are rare primary causes of IPO. Connective tissue disorders such as progressive systemic sclerosis, SLE, and dermatopolymyositis are secondary causes of IPO. Other rare secondary causes of IPO include progressive muscular dystrophy, amyloidosis, diffuse lymphoid infiltration, Parkinson disease, myxedema, pheochromocytoma, and opiate drugs.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p>
      <p>IPO can present as abdominal pain, vomiting, diarrhea and/or constipation, abdominal distension, and weight loss. When the condition worsens, patients may have episodes of severe nausea, vomiting, pain, and distension with x-ray picture that looks like a bowel blockage.</p>
      <p>Gastrointestinal symptoms as the initial manifestations of SLE are non-specific, so the diagnosis is difficult. There were 16 patients whose initial symptom was gastrointestinal symptom. Eleven of them were misdiagnosed and 8 patients had the unnecessary surgery because of misdiagnosed. The main differential diagnosis of IPO in our patient who was eventually diagnosed with SLE was adhesions from her histories of cesarean section and appendectomy. Slightly adhesive intestinal obstruction was observed during the surgery, but it seemed that her slightly adhesive intestinal obstruction couldn&#x2019;t lead to so serious symptoms. The patient vomited again 2 weeks later after the surgery, immunology tests were positive and glucocorticoid therapy was effective. All of these indicated that she had an IPO secondary to SLE.</p>
      <p>There is no cure for SLE, but reasonable treatment can alleviate especially for the early cases. In the 40 cases, 29 patients accepted immunosuppressant as the initial treatment, and 24 of them had a good response. While 11 patients accepted surgery, and all of them relapsed after surgery. Compared with surgical treatment, immunosuppressant has a better efficacy (<italic>P</italic>&#x200A;&lt;&#x200A;0.001). Patients should accept immunosuppressive therapy, which should be gradually tapered. Most of them can rapidly reverse and avert unnecessary surgery.</p>
    </sec>
    <sec sec-type="conclusion">
      <title>CONCLUSION</title>
      <p>The importance of IPO secondary to SLE lies in an accurate diagnosis and corresponding treatment strategy. Immunosuppressive therapy should be the initial and first-line treatment. Surgical intervention and repeated invasive procedures is often disappointing and should be carefully avoided. Physician awareness and accurate diagnosis could positively affect outcomes of this syndrome, avoid complications, bring about resolution of symptoms, and avoiding unnecessary surgical intervention.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: ALB = albumin, anti-dsDNA = anti-double-stranded-DNA antibodies, CRP = C-reaction protein, CT = computed tomography, IgM = immunoglobulin M, IPO = intestinal pseudo-obstruction, SLE = systemic lupus erythematosus.</p>
      </fn>
      <fn fn-type="conflict">
        <p>The authors have no funding or conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>QY</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Darmawan</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Rheumatic diseases in China</article-title>. <source><italic>Arthritis Res Ther</italic></source>
<year>2008</year>; <volume>10</volume>:<fpage>R17</fpage>.<pub-id pub-id-type="pmid">18237382</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Leng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus</article-title>. <source><italic>Lupus</italic></source>
<year>2013</year>; <volume>22</volume>:<fpage>1192</fpage>&#x2013;<lpage>1199</lpage>.<pub-id pub-id-type="pmid">23963101</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Orbai</surname><given-names>AM</given-names></name><name><surname>Alarcon</surname><given-names>GS</given-names></name><etal/></person-group>
<article-title>Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus</article-title>. <source><italic>Arthritis Rheum</italic></source>
<year>2012</year>; <volume>64</volume>:<fpage>2677</fpage>&#x2013;<lpage>2686</lpage>.<pub-id pub-id-type="pmid">22553077</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulou</surname><given-names>A</given-names></name><name><surname>Andrianakos</surname><given-names>A</given-names></name><name><surname>Dourakis</surname><given-names>SP</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction and ureterohydronephrosis as the presenting manifestations of relapse in a lupus patient</article-title>. <source><italic>Lupus</italic></source>
<year>2004</year>; <volume>13</volume>:<fpage>954</fpage>&#x2013;<lpage>956</lpage>.<pub-id pub-id-type="pmid">15645752</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccato</surname><given-names>F</given-names></name><name><surname>Salas</surname><given-names>A</given-names></name><name><surname>Gongora</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases</article-title>. <source><italic>Clin Rheumatol</italic></source>
<year>2008</year>; <volume>27</volume>:<fpage>399</fpage>&#x2013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">17938989</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Xue</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>NS</given-names></name></person-group>
<article-title>Visceral muscle dysmotility syndrome in systemic lupus erythematosus: case report and review of the literature</article-title>. <source><italic>Rheumatol Int</italic></source>
<year>2012</year>; <volume>32</volume>:<fpage>1701</fpage>&#x2013;<lpage>1703</lpage>.<pub-id pub-id-type="pmid">21431943</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Yen</surname><given-names>HH</given-names></name><name><surname>Hsu</surname><given-names>YT</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction as the initial presentation of systemic lupus erythematosus: the need for enteroscopic evaluation</article-title>. <source><italic>Gastrointest Endosc</italic></source>
<year>2005</year>; <volume>62</volume>:<fpage>984</fpage>&#x2013;<lpage>987</lpage>.<pub-id pub-id-type="pmid">16301053</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>LC</given-names></name><name><surname>Laredo-Sanchez</surname><given-names>F</given-names></name><name><surname>Malagon-Rangel</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge</article-title>. <source><italic>World J Gastroenterol</italic></source>
<year>2014</year>; <volume>20</volume>:<fpage>11443</fpage>&#x2013;<lpage>11450</lpage>.<pub-id pub-id-type="pmid">25170234</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>PA</given-names></name><name><surname>Dwyer</surname><given-names>KM</given-names></name><name><surname>Power</surname><given-names>DA</given-names></name></person-group>
<article-title>Chronic intestinal pseudo-obstruction in systemic lupus erythematosus due to intestinal smooth muscle myopathy</article-title>. <source><italic>Lupus</italic></source>
<year>2000</year>; <volume>9</volume>:<fpage>458</fpage>&#x2013;<lpage>463</lpage>.<pub-id pub-id-type="pmid">10981652</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaimes-Hernandez</surname><given-names>J</given-names></name><name><surname>Aranda-Peirera</surname><given-names>P</given-names></name><name><surname>Melendez-Mercado</surname><given-names>CI</given-names></name></person-group>
<article-title>Eosinophilic enteritis in association with systemic lupus erythematosus</article-title>. <source><italic>Lupus</italic></source>
<year>2009</year>; <volume>18</volume>:<fpage>452</fpage>&#x2013;<lpage>456</lpage>.<pub-id pub-id-type="pmid">19318400</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kansal</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Thenozhi</surname><given-names>S</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus</article-title>. <source><italic>Lupus</italic></source>
<year>2013</year>; <volume>22</volume>:<fpage>87</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">23104391</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khairullah</surname><given-names>S</given-names></name><name><surname>Jasmin</surname><given-names>R</given-names></name><name><surname>Yahya</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Chronic intestinal pseudo-obstruction: a rare first manifestation of systemic lupus erythematosus</article-title>. <source><italic>Lupus</italic></source>
<year>2013</year>; <volume>22</volume>:<fpage>957</fpage>&#x2013;<lpage>960</lpage>.<pub-id pub-id-type="pmid">23761180</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>G</given-names></name><name><surname>de Bortoli</surname><given-names>N</given-names></name><name><surname>Bellini</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Intestinal pseudo-obstruction in inactive systemic lupus erythematosus: an unusual finding</article-title>. <source><italic>World J Gastrointest Pharmacol Ther</italic></source>
<year>2010</year>; <volume>1</volume>:<fpage>135</fpage>&#x2013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">21577309</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruoka</surname><given-names>H</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Takeo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Tacrolimus treatment for refractory lupus cystitis</article-title>. <source><italic>Mod Rheumatol</italic></source>
<year>2006</year>; <volume>16</volume>:<fpage>264</fpage>&#x2013;<lpage>266</lpage>.<pub-id pub-id-type="pmid">16906381</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>MY</given-names></name><name><surname>Wong</surname><given-names>RW</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction in systemic lupus erythematosus: an uncommon but important clinical manifestation</article-title>. <source><italic>Lupus</italic></source>
<year>2000</year>; <volume>9</volume>:<fpage>11</fpage>&#x2013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">10713642</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munyard</surname><given-names>P</given-names></name><name><surname>Jaswon</surname><given-names>M</given-names></name></person-group>
<article-title>Systemic lupus erythematosus presenting as intestinal pseudo-obstruction</article-title>. <source><italic>J R Soc Med</italic></source>
<year>1997</year>; <volume>90</volume>:<fpage>48</fpage>&#x2013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">9059386</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narvaez</surname><given-names>J</given-names></name><name><surname>Perez-Vega</surname><given-names>C</given-names></name><name><surname>Castro-Bohorquez</surname><given-names>FJ</given-names></name><etal/></person-group>
<article-title>Intestinal pseudo-obstruction in systemic lupus erythematosus</article-title>. <source><italic>Scand J Rheumatol</italic></source>
<year>2003</year>; <volume>32</volume>:<fpage>191</fpage>&#x2013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">12892261</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Khanna</surname><given-names>N</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction as a presenting manifestation of systemic lupus erythematosus: case report and review of the literature</article-title>. <source><italic>South Med J</italic></source>
<year>2004</year>; <volume>97</volume>:<fpage>186</fpage>&#x2013;<lpage>189</lpage>.<pub-id pub-id-type="pmid">14982272</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardos-Gea</surname><given-names>J</given-names></name><name><surname>Ordi-Ros</surname><given-names>J</given-names></name><name><surname>Selva</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Chronic intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus</article-title>. <source><italic>Lupus</italic></source>
<year>2005</year>; <volume>14</volume>:<fpage>328</fpage>&#x2013;<lpage>330</lpage>.<pub-id pub-id-type="pmid">15864921</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>FD</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Madduri</surname><given-names>GD</given-names></name><name><surname>Ghosh</surname><given-names>P</given-names></name></person-group>
<article-title>Generalized megaviscera of lupus: refractory intestinal pseudo-obstruction, ureterohydronephrosis and megacholedochus</article-title>. <source><italic>World J Gastroenterol</italic></source>
<year>2009</year>; <volume>15</volume>:<fpage>3555</fpage>&#x2013;<lpage>3559</lpage>.<pub-id pub-id-type="pmid">19630114</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlemuter</surname><given-names>G</given-names></name><name><surname>Chaussade</surname><given-names>S</given-names></name><name><surname>Wechsler</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Chronic intestinal pseudo-obstruction in systemic lupus erythematosus</article-title>. <source><italic>Gut</italic></source>
<year>1998</year>; <volume>43</volume>:<fpage>117</fpage>&#x2013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">9771415</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Recurrent paralytic ileus associated with strongyloidiasis in a patient with systemic lupus erythematosus</article-title>. <source><italic>Mod Rheumatol</italic></source>
<year>2006</year>; <volume>16</volume>:<fpage>44</fpage>&#x2013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">16622724</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yukawa</surname><given-names>S</given-names></name><name><surname>Tahara</surname><given-names>K</given-names></name><name><surname>Shoji</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Acute pan-dysautonomia as well as central nervous system involvement and peripheral neuropathies in a patient with systemic lupus erythematosus</article-title>. <source><italic>Mod Rheumatol</italic></source>
<year>2008</year>; <volume>18</volume>:<fpage>516</fpage>&#x2013;<lpage>521</lpage>.<pub-id pub-id-type="pmid">18551352</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Intestinal pseudo-obstruction syndrome in systemic lupus erythematosus</article-title>. <source><italic>Lupus</italic></source>
<year>2011</year>; <volume>20</volume>:<fpage>1324</fpage>&#x2013;<lpage>1328</lpage>.<pub-id pub-id-type="pmid">21680640</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name></person-group>
<article-title>Intestinal pseudo-obstruction: initial manifestation of systemic lupus erythematosus</article-title>. <source><italic>J Neurogastroenterol Motil</italic></source>
<year>2011</year>; <volume>17</volume>:<fpage>423</fpage>&#x2013;<lpage>424</lpage>.<pub-id pub-id-type="pmid">22148114</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki-Nakashimada</surname><given-names>MA</given-names></name><name><surname>Rodriguez-Jurado</surname><given-names>R</given-names></name><name><surname>Ortega-Salgado</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Intestinal pseudoobstruction associated with eosinophilic enteritis as the initial presentation of systemic lupus erythematosus in children</article-title>. <source><italic>J Pediatr Gastroenterol Nutr</italic></source>
<year>2009</year>; <volume>48</volume>:<fpage>482</fpage>&#x2013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">19330936</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><etal/></person-group>
<article-title>Clinical analysis of systemic lupus erythematosus with gastrointestinal manifestations</article-title>. <source><italic>Lupus</italic></source>
<year>2010</year>; <volume>19</volume>:<fpage>866</fpage>&#x2013;<lpage>869</lpage>.<pub-id pub-id-type="pmid">20410154</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Sleisenger</surname><given-names>MH</given-names></name></person-group>
<edition>6th ed</edition><article-title>Sleisenger &amp; Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management</article-title>. <volume> Vol 2</volume>: <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>W.B. Saunders</publisher-name>; <year>1998</year>
<fpage>1821</fpage>&#x2013;<lpage>1830</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
